Dronabinol; Cannabidiol for Tuberous sclerosis complex | Refractory epilepsy

Inclusion criteria

• {"criterion_text":"- Patients of any sex between 2 and 65 years of age (both included)"}
• {"criterion_text":"- Diagnosis confirmed by the TSC investigator (by clinical criteria and/or genetic study)."}
• {"criterion_text":"- Refractory epilepsy secondary to TSC, defined as that not responding successfully to traditional AEDs (2 or more), ketogenic diet, vagal nerve stimulator, and/or whose patients are not candidate for epilepsy surgery or persist with seizures after surgery."}
• {"criterion_text":"- Patients with a minimum of 4 epileptic seizures or more within 4 weeks prior to the initiation of the assigned treatment in the trial, with observable external signs (loss of consciousness or motor component)."}
• {"criterion_text":"- Stability in AEDs doses, and in ketogenic diet/programming of the device associated with the vagal nerve stimulator with no changes for at least 4 weeks prior to the initiation of the assigned treatment."}
• {"criterion_text":"- Patients who are in treatment with 3 or less AEDs at the time of signing the informed consent. For the purposes of assessing eligibility, Clobazam will not be counted as AED"}
• {"criterion_text":"- Willingness by patients or caregivers/family members (in case of patients who are minors or under legal guardianship) to complete the seizure diary."}
• {"criterion_text":"- In case of women of child-bearing age, for safety, those who agree to follow the required contraceptive measures from the signing of the informed consent until three months after stop the intake of the investigational medicinal product."}
• {"criterion_text":"- Patients who have signed the informed consent either by themselves or through a legal representative."}

Exclusion criteria

• {"criterion_text":"- Patients who are receiving treatment on corticoids at the time of signing the informed consent."}
• {"criterion_text":"- Patients who did not correctly follow the AED treatment in the 4 weeks prior to the intervention assigned in the trial."}
• {"criterion_text":"- Patients who changed medication or AED dose, ketogenic diet, or the vagal stimulator during the 4 weeks prior to the initiation of the intervention assigned in the trial."}
• {"criterion_text":"- Cardiac, renal, and hepatic failure, pancreatic insufficiency, or hematologic dysfunction with values above the normal limits of creatinine and urea; values 2 times the normal limits of transaminases, lipases, and serum amylase; platelets < 80000/mm3, and white blood cell count <3000/mm3."}
• {"criterion_text":"- Uncontrolled severe medical condition such as: hepatic disease, increased bilirubin levels more than twice the normal limit, cirrhosis, chronic hepatitis (hepatitis B or C), uncontrolled diabetes (defined as blood glucose >150 mg%), (chronic or acute) active infections or uncontrolled severe infections, or active bleeding."}
• {"criterion_text":"- Patients or family/caregivers (in case of patients who are minors or under legal guardianship) who does not agree to comply with the requirements and trial visits or present a high risk of non-compliance with the protocol, according to the treating physician."}
• {"criterion_text":"- Allergy to any of the components of the investigational medicinal product/placebo."}
• {"criterion_text":"- Family (considering only first-degree blood relatives) or personal history of schizophrenia."}
• {"criterion_text":"- Personal history of suicide attempts."}
• {"criterion_text":"- Pregnancy."}
• {"criterion_text":"- Breastfeeding women"}
• {"criterion_text":"- To have participated in another clinical trial, unless at least 5 half- lives of the investigational product have elapsed, or 12 weeks, if it is a product with cannabis oil."}
• {"criterion_text":"- Patients who have received products with cannabis oil in the last 12 weeks."}

Primary endpoints

• {"endpoint_text":"- Comparison of the number of monthly seizures since the initiation of the treatment with YCJ-01 with respect to the baseline period: in patients assigned to receive YCJ-01, change in the number of monthly seizures in the second month of treatment with respect to the baseline period; and in patient assigned to receive a placebo, changes in the number of monthly seizures in the second month of treatment with YCJ-01 with respect to the baseline period.","definition_or_measurement_approach":"Change in number of monthly seizures comparing the second month of treatment versus baseline period (baseline defined by visits P0 to P1); comparison between YCJ-01 and placebo arms."}
• {"endpoint_text":"- Occurrence of Adverse Events (AE), Severe AE (SAE), AE resulting in study treatment withdrawal, AE of special interest (AESI), and changes in vital signs and laboratory values during the clinical trial. (Variable associated to the primary objective 2).","definition_or_measurement_approach":"Monitoring and recording of AEs/SAEs/AESIs and changes in vital signs and laboratory values throughout the trial period; event counts and related safety assessments."}

Secondary endpoints

• {"endpoint_text":"- Comparison of the number of monthly epileptic seizures between the two treatment groups and the baseline period: change in number of monthly seizures of patients assigned to receive the investigational medicinal product during the second month of treatment (from visit P2 to P3) with respect of the baseline period (from visit P0 to P1), in comparison to the second month of treatment (from visit P2 to P3) to the group receiving placebo with respect to the baseline period (from visit P0 to P1).","definition_or_measurement_approach":"Comparison of monthly seizure counts between groups at specified visits (P2 to P3) vs baseline (P0 to P1)."}
• {"endpoint_text":"- Comparison of the number of monthly seizures since the initiation of the treatment with YCJ-01 with respect to the baseline period: in patients assigned to receive YCJ-01, change in the number of monthly seizures in the months of treatment after the second month of treatment with respect to the baseline period; and in patients assigned to receive placebo, changes in the number of monthly seizures in the months of treatment after the second month of treatment with YCJ-01 with respect to baseline","definition_or_measurement_approach":"Longitudinal comparison of monthly seizure counts after month 2 versus baseline period."}
• {"endpoint_text":"- Comparison of the number of monthly seizures once the final dose was reached in P4-P5 with respect to the baseline period (from visit P0 to P1) in each of the patients. (Variable associated with primary objective 1).","definition_or_measurement_approach":"Comparison of monthly seizure counts at visits P4-P5 (final dose reached) versus baseline (P0-P1)."}
• {"endpoint_text":"- Response rate to YCJ-01: patients who achieve a decrease of at least a 50 % of the number of epileptic seizures with respect to the baseline period (from visit P0 to P1) in visits P3, P4, P6, and P7 will be considered responders. (Variable associated to the secondary objective 1).","definition_or_measurement_approach":"Proportion of patients with >=50% reduction in seizure count versus baseline at visits P3, P4, P6, P7."}
• {"endpoint_text":"- Response rate to YCJ-01in comparison to the placebo group: patients who achieve a decrease in at least a 50 % of the number of epileptic seizures with respect to the baseline period (from visit P0 to P1) in visit P3 will be considered responders. (Variable associated to the secondary objective 1).","definition_or_measurement_approach":"Comparison of responder rates (>=50% seizure reduction) between YCJ-01 and placebo at visit P3."}
• {"endpoint_text":"- Proportion of subjects in treatment with YCJ-01 achieving a 25%, 50%, 75%, 90% reduction in the number of epileptic seizures with respect to the baseline period (from visit P0 to P1) at visits P3, P4, P6, and P7. (Variable associated to the secondary objective 2).","definition_or_measurement_approach":"Proportions of patients achieving specified percent reductions in seizure counts at listed visits versus baseline."}
• {"endpoint_text":"- Proportion of subjects in treatment with YCJ-01 compared to placebo group achieving a 25%, 50%, 75%, 90% reduction in the number of epileptic seizures with respect to the baseline period (from visit P0 to P1) at visit P3. (Variable associated to the secondary objective 2).","definition_or_measurement_approach":"Comparison of proportions achieving specified seizure-reduction thresholds at visit P3 between arms."}
• {"endpoint_text":"- Proportion of patients in treatment with YCJ-01 free of epileptic seizures: defined as those participants with no seizure of any type from the initiation of the treatment with YCJ-01 till visit P7, or a period of time that doubles the baseline maximum interval between seizures (International League Against Epilepsy, ILAE). (Variable associated with the secondary objective 3).","definition_or_measurement_approach":"Proportion of patients with no seizures from treatment initiation until visit P7 (or doubling of baseline max interseizure interval as per ILAE)."}
• {"endpoint_text":"- Proportion of patients in treatment with YCJ-01 free of epileptic seizures in comparison to the placebo group: defined as those participants with no seizure of any type from the initiation of the assigned treatment till visit P7, or a period of time that doubles the baseline maximum interval between seizures (International League Against Epilepsy, ILAE). (Variable associated with the secondary objective 3).","definition_or_measurement_approach":"Comparison of seizure-free proportions between YCJ-01 and placebo up to visit P7 (or ILAE doubling rule)."}
• {"endpoint_text":"- Effect on control of epileptic seizures (variable associated to the secondary objective 4): Changes in severity and in types of epileptic seizures will be assessed after the initiation of the treatment (from visit P1 to P2, from visit P2 to P3, from visit P3 to P4, from visit P4 to P5, from visit P5 to P6, from visit P6 to P7) with respect to the baseline period (form visit P0 to P1).","definition_or_measurement_approach":"Assessment of changes in seizure severity and seizure types at sequential visits compared with baseline (P0-P1)."}

Methods

• Flyer on sponsor's website and hospital publications targeted at patients in Spain (document titled 'K2_SPECTRUM_Flyer_Sponsor s web and hospital publication for patients_Spain_ES_for pub').

Spain

Earliest CTIS Part Ii Submission Date

11-12-2024

Latest Decision Or Authorization Date

07-08-2025

Processing Time Days

239

Number Of Sites

4

Number Of Participants

84

Primary sponsor

Full Name

Oils4cure S.L.

Organisation Type

Pharmaceutical company

Country Of Registered Address

Spain

Contract research organisations

Name

Sermes CRO

Responsibilities

Sponsor duties codes: 1,10,11,12,3,6,7,8

Third parties

• {"country":"Spain","full_name":"Sermes CRO","duties_or_roles":"sponsor duties codes: 1,10,11,12,3,6,7,8","organisation_type":"Pharmaceutical company"}
• {"country":"Spain","full_name":"Eurofins Megalab S.A.","duties_or_roles":"sponsor duties codes: 4","organisation_type":"Laboratory/Research/Testing facility"}